Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.23 -0.67%

-$0.09 today

Market cap
$239.70M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.81M

Average 0.17M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$19.27M

FY 2025 · Annual

Investing Cash Flow

$40.35M

FY 2025 · Annual

-30.7% YoY

Financing Cash Flow

-$26.62M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(79M)(121.76M)(133.82M)(116.05M)(81.89M)
Depreciation & Amortization3.33M2.97M2.37M2.34M5.09M
Deferred Income Tax345K0000
Stock-Based Compensation20.99M26.97M28.22M26.8M18.57M
Change in Working Capital(13.69M)6.79M8.02M7.13M39.91M
Accounts Receivables(24.3M)11.8M9.42M973K31.76M
Inventory00000
Accounts Payables3.77M(4.63M)(1.15M)(414K)(1.31M)
Other Working Capital6.84M(372K)(243K)6.57M9.46M
Other Non-Cash Items(1.98M)242K(7.95M)1.02M(946K)
Operating Cash Flow(70M)(84.78M)(103.15M)(78.76M)(19.27M)
Capital Expenditures(750K)(2.13M)(9.06M)(17.95M)(12.9M)
Acquisitions (Net)(37.74M)(54.9M)44.52M00
Purchases of Investments(307.35M)(171.45M)(373.39M)(307.28M)(209.63M)
Sales of Investments345.09M228.47M328.87M383.47M262.87M
Other Investing Activities37.74M54.9M(44.52M)00
Investing Cash Flow36.99M54.9M(53.58M)58.24M40.35M
Debt Repayment00199.68M(27.48M)(26.49M)
Common Stock Issued3.61M21.26M2.21M147K145K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(534K)(1.23M)(3.76M)(294K)(277K)
Financing Cash Flow3.08M20.03M198.13M(27.63M)(26.62M)
Effect of Forex Changes00000
Net Change in Cash(29.93M)(9.85M)41.39M(48.16M)(5.54M)
Free Cash Flow(70.75M)(86.91M)(112.21M)(96.71M)(32.17M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$81.9M
+ D&A$5.1M
+ Stock-Based Comp$18.6M
+ Deferred Tax$0
+ Working Capital$39.9M
- Other Non-Cash-$946.0K
= Operating Cash Flow-$19.3M
- Capex-$12.9M
= Free Cash Flow-$32.2M

Analysis

FY2025 free cash flow is -$32.2M. FCF conversion is 39.3% of net income. Operating cash flow was -$19.3M, with capex of -$12.9M. The largest bridge item is Working Capital at $39.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportOct 29, 2026
8-KCurrent reportOct 28, 2026
SC 13GSC 13G filingOct 27, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

Does ENTA generate free cash flow?

Enanta Pharmaceuticals, Inc. (ENTA) generated -$32.17M of free cash flow in fiscal 2025.

How much operating cash flow does ENTA produce?

Operating cash flow was -$19.27M, before capital expenditures of $12.90M.